Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD22 Positive”

38 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 38 results

Early research (Phase 1)Temporarily pausedNCT00077493
What this trial is testing

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 95
Large-scale testing (Phase 3)Ended earlyNCT01232556
What this trial is testing

Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Who this might be right for
Lymphoma, Non-Hodgkin
Pfizer 338
Early research (Phase 1)UnknownNCT05523661
What this trial is testing

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

Who this might be right for
Ph Positive ALLCAR-T CellDasatinib
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 15
Early research (Phase 1)WithdrawnNCT00024115
What this trial is testing

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Study completedNCT01564784
What this trial is testing

Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Pfizer 326
Post-approval studies (Phase 4)Study completedNCT05687032
What this trial is testing

Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Pfizer 44
Early research (Phase 1)Active Not RecruitingNCT03241940
What this trial is testing

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+4 more
Stanford University 33
Testing effectiveness (Phase 2)Ended earlyNCT03698552
What this trial is testing

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Blasts 5 Percent or More of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome Positive+2 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Looking for participantsNCT03739814
What this trial is testing

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) 64
Testing effectiveness (Phase 2)Ended earlyNCT03913559
What this trial is testing

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital 5
Testing effectiveness (Phase 2)Study completedNCT02311998
What this trial is testing

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Who this might be right for
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+4 more
M.D. Anderson Cancer Center 22
Testing effectiveness (Phase 2)Study completedNCT01664910
What this trial is testing

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Who this might be right for
Hematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center 27
Early research (Phase 1)UnknownNCT04204161
What this trial is testing

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Who this might be right for
Relapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, Childhood
Shenzhen BinDeBio Ltd. 30
Testing effectiveness (Phase 2)Study completedNCT01363297
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia
Pfizer 72
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Early research (Phase 1)UnknownNCT04303520
What this trial is testing

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Who this might be right for
CD19-positive ALL
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Early research (Phase 1)Looking for participantsNCT06752785
What this trial is testing

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Who this might be right for
Acute Lymphoblastic Leukemia
Guangzhou Women and Children's Medical Center 10
Testing effectiveness (Phase 2)WithdrawnNCT04029038
What this trial is testing

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Who this might be right for
CD19 PositiveCD22 PositiveMinimal Residual Disease+7 more
M.D. Anderson Cancer Center
Early research (Phase 1)UnknownNCT03999697
What this trial is testing

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Who this might be right for
Diffuse Large B Cell LymphomaFollicular LymphomaPrimary Cutaneous Follicle Centre Lymphoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT04788472
What this trial is testing

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

Who this might be right for
B-Cell Acute Lymphoblastic Leukemia, Adult
Zhejiang University 28
Load More Results